Virax Biolabs Group shares surge 73.86% intraday after completing recruitment for VRX-002 and VRX-003 trials and partnering with Emory University.

Virax Biolabs Group surged 73.86% intraday, as the company announced the completion of participant recruitment for its UK VRX-002 study (160 participants) with initial data expected in Q2 2026, and the full enrollment of 100 participants in the UK VRX-003 study, alongside a research collaboration with Emory University in the US.